[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-001", "question": "A 3-day-old term neonate presents with progressive cyanosis unresponsive to supplemental oxygen. Echocardiography reveals d-transposition of the great arteries with intact ventricular septum and a restrictive patent foramen ovale. Prostaglandin E1 infusion is initiated but cyanosis persists with oxygen saturation of 55%. The infant is hemodynamically stable with adequate biventricular function. Which of the following is the most appropriate next step in management?", "options": ["Emergent arterial switch operation", "Balloon atrial septostomy", "Extracorporeal membrane oxygenation", "Inhaled nitric oxide therapy", "Atrial septectomy via median sternotomy"], "answer": "B", "answer_index": 1, "explanation": "In d-TGA with intact ventricular septum and restrictive atrial communication, balloon atrial septostomy (Rashkind procedure) is the urgent intervention to improve mixing at the atrial level. PGE1 maintains ductal patency but cannot improve atrial mixing when the foramen ovale is restrictive. Arterial switch is definitive but requires stabilization first. ECMO is reserved for refractory cases after septostomy. Surgical septectomy is more invasive and reserved for failed balloon septostomy.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 3‑day‑old term neonate; severe progressive cyanosis unresponsive to oxygen; echocardiography shows d‑TGA with intact ventricular septum and *restrictive* PFO; PGE1 started but sats remain 55%; hemodynamically stable with good biventricular function. These findings indicate inadequate interatrial mixing despite ductal patency, making urgent augmentation of atrial-level shunting the priority.\\nBalloon atrial septostomy (Rashkind) is the standard urgent intervention to enlarge the atrial communication in d‑TGA with restrictive PFO, allowing improved oxygenated–deoxygenated blood mixing and increased systemic oxygen saturation prior to definitive arterial switch.\\nOption A (emergent arterial switch) is definitive repair but not the immediate step; the infant first requires stabilization and improved mixing. Option C (ECMO) is reserved for severe hemodynamic compromise or failure/contraindication of septostomy. Option D (inhaled nitric oxide) targets pulmonary hypertension, not mixing, and is not indicated here. Option E (surgical septectomy) is a more invasive alternative when balloon septostomy is not feasible or unsuccessful.\\nMain medical accuracy issues: none significant; reasoning and hierarchy of interventions are guideline-consistent.\\nMinimal fix: Explicitly note that septostomy is feasible (e.g., appropriate atrial anatomy and catheter access) to remove any hypothetical ambiguity with surgical septectomy or ECMO options.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 3‑day‑old term neonate; severe progressive cyanosis unresponsive to oxygen; echocardiography shows d‑TGA with intact ventricular septum and *restrictive* PFO; PGE1 started but sats remain 55%; hemodynamically stable with good biventricular function. These findings indicate inadequate interatrial mixing despite ductal patency, making urgent augmentation of atrial-level shunting the priority.\nBalloon atrial septostomy (Rashkind) is the standard urgent intervention to enlarge the atrial communication in d‑TGA with restrictive PFO, allowing improved oxygenated–deoxygenated blood mixing and increased systemic oxygen saturation prior to definitive arterial switch.\nOption A (emergent arterial switch) is definitive repair but not the immediate step; the infant first requires stabilization and improved mixing. Option C (ECMO) is reserved for severe hemodynamic compromise or failure/contraindication of septostomy. Option D (inhaled nitric oxide) targets pulmonary hypertension, not mixing, and is not indicated here. Option E (surgical septectomy) is a more invasive alternative when balloon septostomy is not feasible or unsuccessful.\nMain medical accuracy issues: none significant; reasoning and hierarchy of interventions are guideline-consistent.\nMinimal fix: Explicitly note that septostomy is feasible (e.g., appropriate atrial anatomy and catheter access) to remove any hypothetical ambiguity with surgical septectomy or ECMO options.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-002", "question": "A 58-year-old woman with longstanding rheumatoid arthritis on methotrexate and adalimumab presents with 6 weeks of progressive dyspnea and dry cough. HRCT shows diffuse ground-glass opacities with areas of consolidation in a peribronchovascular distribution. Bronchoalveolar lavage reveals 45% lymphocytes with CD4/CD8 ratio of 0.5. Methotrexate pneumonitis is suspected. Which histopathologic pattern is most commonly associated with methotrexate-induced lung toxicity?", "options": ["Usual interstitial pneumonia", "Diffuse alveolar damage", "Hypersensitivity pneumonitis pattern", "Organizing pneumonia", "Pulmonary alveolar proteinosis"], "answer": "C", "answer_index": 2, "explanation": "Methotrexate-induced lung toxicity most commonly manifests as a hypersensitivity pneumonitis pattern, characterized by lymphocytic alveolitis with low CD4/CD8 ratio, granulomas, and interstitial inflammation. The BAL findings of elevated lymphocytes with inverted CD4/CD8 ratio support this diagnosis. While organizing pneumonia and diffuse alveolar damage can occur, hypersensitivity pneumonitis is the predominant pattern. UIP pattern is more characteristic of RA-ILD itself rather than drug toxicity.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Longstanding RA treated with methotrexate; subacute (6-week) onset of dyspnea and dry cough; HRCT with diffuse ground-glass and peribronchovascular consolidation; BAL with 45% lymphocytes and low CD4/CD8 ratio (0.5); explicit suspicion of methotrexate pneumonitis. These features are classic for a drug-induced hypersensitivity pneumonitis–type reaction rather than RA-associated UIP or other ILD patterns.\\nThe keyed answer (C, hypersensitivity pneumonitis pattern) aligns with standard teaching that methotrexate lung toxicity most often shows an HP-like pattern histologically, with lymphocytic alveolitis and granulomatous/interstitial inflammation. Diffuse alveolar damage and organizing pneumonia are recognized but less common patterns; UIP is more typical of RA-ILD itself, and pulmonary alveolar proteinosis is not characteristically linked to methotrexate.\\nLogical structure is sound: one clearly superior option, no internal contradictions, and choices are mutually distinguishable histopathologic patterns. No significant medical inaccuracies are evident; explanation correctly differentiates drug toxicity from underlying RA-ILD.\\nMinimal fix: Add a brief line in the stem such as “Transbronchial biopsy shows interstitial lymphocytic infiltrates and poorly formed granulomas” to more tightly link clinical data to the histopathologic pattern being asked about, though current item is already answerable.\\n\",\n  \"medical_accuracy_score\":  \"5\",\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Longstanding RA treated with methotrexate; subacute (6-week) onset of dyspnea and dry cough; HRCT with diffuse ground-glass and peribronchovascular consolidation; BAL with 45% lymphocytes and low CD4/CD8 ratio (0.5); explicit suspicion of methotrexate pneumonitis. These features are classic for a drug-induced hypersensitivity pneumonitis–type reaction rather than RA-associated UIP or other ILD patterns.\nThe keyed answer (C, hypersensitivity pneumonitis pattern) aligns with standard teaching that methotrexate lung toxicity most often shows an HP-like pattern histologically, with lymphocytic alveolitis and granulomatous/interstitial inflammation. Diffuse alveolar damage and organizing pneumonia are recognized but less common patterns; UIP is more typical of RA-ILD itself, and pulmonary alveolar proteinosis is not characteristically linked to methotrexate.\nLogical structure is sound: one clearly superior option, no internal contradictions, and choices are mutually distinguishable histopathologic patterns. No significant medical inaccuracies are evident; explanation correctly differentiates drug toxicity from underlying RA-ILD.\nMinimal fix: Add a brief line in the stem such as “Transbronchial biopsy shows interstitial lymphocytic infiltrates and poorly formed granulomas” to more tightly link clinical data to the histopathologic pattern being asked about, though current item is already answerable.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-003", "question": "A 32-year-old woman at 28 weeks gestation presents with severe preeclampsia. Despite magnesium sulfate and labetalol, she develops pulmonary edema requiring intubation. Echocardiography shows preserved ejection fraction of 65% with grade III diastolic dysfunction and elevated E/e' ratio of 18. Central venous pressure is 4 mmHg. Which pathophysiologic mechanism best explains her pulmonary edema?", "options": ["Systolic heart failure from peripartum cardiomyopathy", "Increased pulmonary capillary permeability from endothelial dysfunction", "Volume overload from iatrogenic fluid administration", "Diastolic dysfunction from acute afterload mismatch", "Mitral regurgitation from papillary muscle dysfunction"], "answer": "D", "answer_index": 3, "explanation": "Severe preeclampsia causes acute hypertensive crisis leading to afterload mismatch. The preserved EF with grade III diastolic dysfunction and elevated E/e' indicates heart failure with preserved ejection fraction due to impaired ventricular relaxation from acute pressure overload. The low CVP argues against volume overload. While endothelial dysfunction occurs in preeclampsia, the echocardiographic findings point to diastolic dysfunction as the primary mechanism. Peripartum cardiomyopathy would show reduced systolic function.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Severe preeclampsia with hypertensive crisis, pulmonary edema; echo showing preserved EF (65%) but grade III diastolic dysfunction and elevated E/e’ (18) → elevated LV filling pressures with HFpEF; central venous pressure low-normal at 4 mmHg, arguing against marked volume overload; no mention of valvular disease. These support acute afterload-driven diastolic failure as mechanism.\\nOption analysis: A (systolic HF from peripartum cardiomyopathy) conflicts with preserved EF and is typically later peripartum; ruled out. B (increased pulmonary capillary permeability) is a known contributor in preeclampsia but item specifically gives detailed echo data emphasizing hydrostatic mechanism; permeability is secondary and less best as single mechanism. C (volume overload) is inconsistent with low CVP. D (diastolic dysfunction from acute afterload mismatch) directly matches echo findings and pathophysiology of hypertensive pulmonary edema in preeclampsia. E (mitral regurgitation) would usually present with structural or Doppler evidence, not provided.\\nMain medical accuracy issues: Minor—preeclampsia pathogenesis also involves endothelial permeability, but question targets hydrostatic HFpEF mechanism.\\nMinimal fix: In stem, explicitly state severely elevated blood pressure values to further emphasize acute hypertensive afterload mismatch as primary cause.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Severe preeclampsia with hypertensive crisis, pulmonary edema; echo showing preserved EF (65%) but grade III diastolic dysfunction and elevated E/e’ (18) → elevated LV filling pressures with HFpEF; central venous pressure low-normal at 4 mmHg, arguing against marked volume overload; no mention of valvular disease. These support acute afterload-driven diastolic failure as mechanism.\nOption analysis: A (systolic HF from peripartum cardiomyopathy) conflicts with preserved EF and is typically later peripartum; ruled out. B (increased pulmonary capillary permeability) is a known contributor in preeclampsia but item specifically gives detailed echo data emphasizing hydrostatic mechanism; permeability is secondary and less best as single mechanism. C (volume overload) is inconsistent with low CVP. D (diastolic dysfunction from acute afterload mismatch) directly matches echo findings and pathophysiology of hypertensive pulmonary edema in preeclampsia. E (mitral regurgitation) would usually present with structural or Doppler evidence, not provided.\nMain medical accuracy issues: Minor—preeclampsia pathogenesis also involves endothelial permeability, but question targets hydrostatic HFpEF mechanism.\nMinimal fix: In stem, explicitly state severely elevated blood pressure values to further emphasize acute hypertensive afterload mismatch as primary cause.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-004", "question": "A 67-year-old man with ischemic cardiomyopathy (EF 25%) and cardiac resynchronization therapy-defibrillator presents after appropriate ICD shock for ventricular tachycardia. He is on maximally tolerated guideline-directed medical therapy including sacubitril-valsartan, carvedilol, spironolactone, and dapagliflozin. Electrophysiology study reveals scar-related reentrant VT from the inferolateral left ventricle. Catheter ablation is performed. Three months later, he has recurrent VT storm despite amiodarone. Which additional pharmacologic therapy has demonstrated mortality benefit in this specific population?", "options": ["Mexiletine", "Sotalol", "Ranolazine", "Quinidine", "Dofetilide"], "answer": "A", "answer_index": 0, "explanation": "Mexiletine, a class IB sodium channel blocker, when added to amiodarone in patients with recurrent VT despite amiodarone monotherapy, has shown reduction in VT recurrence and ICD shocks. The MEXICA trial demonstrated this combination's efficacy. Sotalol and dofetilide have proarrhythmic risks in low EF patients. Quinidine has significant toxicity and limited modern data. Ranolazine has some antiarrhythmic properties but lacks robust evidence in scar-related VT. Mexiletine's synergistic sodium channel blockade with amiodarone provides additional substrate modification.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N\\nVerdict on keyed answer: No defensible answer as written (question asks about mortality benefit; none of the options have proven mortality benefit for this indication)\\n\\nKey stem clues: Ischemic cardiomyopathy with EF 25%, CRT-D, scar-related VT, post-ablation VT storm despite amiodarone; question explicitly: “Which additional pharmacologic therapy has demonstrated mortality benefit in this specific population?” This is narrowly asking for *mortality benefit*, not just VT/ICD shock reduction.\\n\\nMain logical issue(s): The keyed answer (mexiletine) has some data for reducing VT episodes/ICD shocks as add-on to amiodarone, but there is no robust evidence of a mortality benefit specific to this population. None of the listed drugs (including sotalol, dofetilide, quinidine, ranolazine) have demonstrated mortality benefit in this scenario; several have known increased mortality or significant proarrhythmia in low-EF patients. Thus the stem’s request (mortality benefit) is not satisfied by any option, so the item has no defensible correct answer.\\n\\nMain medical accuracy issue(s): Conflation of reduced VT recurrence/ICD shocks with mortality benefit.\\n\\nMinimal fix: Change the stem to “has demonstrated reduction in VT recurrence and ICD shocks” instead of “mortality benefit,” keeping mexiletine as the correct answer.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N\nVerdict on keyed answer: No defensible answer as written (question asks about mortality benefit; none of the options have proven mortality benefit for this indication)\n\nKey stem clues: Ischemic cardiomyopathy with EF 25%, CRT-D, scar-related VT, post-ablation VT storm despite amiodarone; question explicitly: “Which additional pharmacologic therapy has demonstrated mortality benefit in this specific population?” This is narrowly asking for *mortality benefit*, not just VT/ICD shock reduction.\n\nMain logical issue(s): The keyed answer (mexiletine) has some data for reducing VT episodes/ICD shocks as add-on to amiodarone, but there is no robust evidence of a mortality benefit specific to this population. None of the listed drugs (including sotalol, dofetilide, quinidine, ranolazine) have demonstrated mortality benefit in this scenario; several have known increased mortality or significant proarrhythmia in low-EF patients. Thus the stem’s request (mortality benefit) is not satisfied by any option, so the item has no defensible correct answer.\n\nMain medical accuracy issue(s): Conflation of reduced VT recurrence/ICD shocks with mortality benefit.\n\nMinimal fix: Change the stem to “has demonstrated reduction in VT recurrence and ICD shocks” instead of “mortality benefit,” keeping mexiletine as the correct answer.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-005", "question": "A 6-year-old boy presents with recurrent episodes of fever, cervical lymphadenopathy, aphthous stomatitis, and pharyngitis occurring every 4-6 weeks since age 2. Episodes resolve spontaneously within 5 days. Between episodes, he is completely well with normal growth. Laboratory studies during an episode show elevated CRP and ESR with normal complete blood count. Genetic testing for FMF, TRAPS, and HIDS mutations is negative. Which treatment has the highest likelihood of inducing complete remission?", "options": ["Colchicine prophylaxis", "Anakinra during episodes", "Single-dose corticosteroid at episode onset", "Tonsillectomy with or without adenoidectomy", "Cimetidine prophylaxis"], "answer": "D", "answer_index": 3, "explanation": "PFAPA syndrome (Periodic Fever, Aphthous stomatitis, Pharyngitis, Adenitis) is the most common periodic fever syndrome in children. While corticosteroids abort individual episodes, they may shorten the interval between attacks. Tonsillectomy (with or without adenoidectomy) achieves complete resolution in 63-95% of patients and is considered curative. Colchicine and cimetidine have variable efficacy for prophylaxis. Anakinra is reserved for refractory cases. The classic presentation with negative genetic testing and stereotypical episodes strongly supports PFAPA, where tonsillectomy offers the best chance of definitive cure.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 6-year-old boy; recurrent stereotyped fevers every 4–6 weeks since age 2; aphthous stomatitis, pharyngitis, cervical adenitis; spontaneous resolution in ~5 days; completely well and normally growing between episodes; elevated inflammatory markers with otherwise normal labs; negative genetic testing for FMF/TRAPS/HIDS. This is a classic PFAPA syndrome presentation. The question asks which treatment has the highest likelihood of inducing complete remission.\\nAmong listed options, tonsillectomy (± adenoidectomy) is well supported in the literature as having the highest complete remission rates (roughly two-thirds to >90%) and is often considered curative. Single-dose corticosteroids at onset reliably abort episodes but do not generally induce long-term remission and may shorten inter-episode interval. Colchicine and cimetidine show variable/partial prophylactic benefit; anakinra is mainly for refractory autoinflammatory conditions and not first-line curative therapy in PFAPA. Thus D is the single best answer.\\nMain logical issue(s): none significant; stem and options allow unique best choice.\\nMain medical accuracy issues: none; teaching point and data are contemporary and consistent with pediatric rheumatology literature.\\nMinimal fix: Optionally specify “PFAPA is suspected” in the stem to make the intended diagnosis explicit, though it is already strongly implied.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 6-year-old boy; recurrent stereotyped fevers every 4–6 weeks since age 2; aphthous stomatitis, pharyngitis, cervical adenitis; spontaneous resolution in ~5 days; completely well and normally growing between episodes; elevated inflammatory markers with otherwise normal labs; negative genetic testing for FMF/TRAPS/HIDS. This is a classic PFAPA syndrome presentation. The question asks which treatment has the highest likelihood of inducing complete remission.\nAmong listed options, tonsillectomy (± adenoidectomy) is well supported in the literature as having the highest complete remission rates (roughly two-thirds to >90%) and is often considered curative. Single-dose corticosteroids at onset reliably abort episodes but do not generally induce long-term remission and may shorten inter-episode interval. Colchicine and cimetidine show variable/partial prophylactic benefit; anakinra is mainly for refractory autoinflammatory conditions and not first-line curative therapy in PFAPA. Thus D is the single best answer.\nMain logical issue(s): none significant; stem and options allow unique best choice.\nMain medical accuracy issues: none; teaching point and data are contemporary and consistent with pediatric rheumatology literature.\nMinimal fix: Optionally specify “PFAPA is suspected” in the stem to make the intended diagnosis explicit, though it is already strongly implied.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-006", "question": "A 45-year-old woman with systemic lupus erythematosus develops acute kidney injury with serum creatinine rising from 1.0 to 3.8 mg/dL over 2 weeks. Urinalysis shows 3+ protein, numerous RBC casts, and dysmorphic red cells. Complement levels are low. Kidney biopsy reveals diffuse proliferative glomerulonephritis (Class IV-G) with 40% cellular crescents, wire loop lesions, and activity index of 14/24 with chronicity index of 2/12. Anti-dsDNA antibody titer is markedly elevated. Which induction regimen has demonstrated superior renal response rates in this clinical scenario?", "options": ["Mycophenolate mofetil plus glucocorticoids", "Cyclophosphamide (Euro-Lupus protocol) plus glucocorticoids", "Voclosporin plus mycophenolate mofetil plus glucocorticoids", "Rituximab plus mycophenolate mofetil plus glucocorticoids", "Belimumab plus cyclophosphamide plus glucocorticoids"], "answer": "C", "answer_index": 2, "explanation": "The AURORA trial demonstrated that voclosporin added to mycophenolate mofetil and low-dose glucocorticoids achieved significantly higher complete renal response rates (41% vs 23%) at 52 weeks compared to MMF and glucocorticoids alone in active lupus nephritis. This triple therapy showed benefit across Class III, IV, and V lupus nephritis. While MMF and cyclophosphamide are established induction agents, the addition of voclosporin (a novel calcineurin inhibitor) provides superior efficacy. Rituximab and belimumab combinations lack the same level of evidence for superior renal response in this setting.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Middle‑aged woman with SLE; biopsy-proven diffuse proliferative LN (Class IV-G) with high activity, low chronicity, low complements, high anti-dsDNA → active severe lupus nephritis needing induction. Question explicitly: “Which induction regimen has demonstrated superior renal response rates in this clinical scenario?” implying evidence-based regimen with proven superiority over standard MMF+steroids.\\nThe AURORA-1 trial showed that voclosporin added to MMF and steroids improved complete renal response vs MMF+steroids alone across proliferative classes, matching the rationale and keyed answer C. MMF+steroids (A) and Euro-Lupus cyclophosphamide+steroids (B) are acceptable standard inductions but have not been shown superior to MMF+steroids in this specific head‑to‑head way in this setting. Rituximab (D) and belimumab with cyclophosphamide (E) lack strong RCT data demonstrating superior induction response versus MMF+steroids for initial treatment of active Class IV-G LN.\\nThus, a unique best option exists and matches the key.\\nMain medical accuracy issue: none; summary of AURORA results is accurate at board level, though real‑world guideline adoption is evolving.\\nMinimal fix: Add phrase “based on randomized controlled trial evidence showing superiority over MMF plus glucocorticoids alone” to the stem to emphasize the trial-comparison context.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Middle‑aged woman with SLE; biopsy-proven diffuse proliferative LN (Class IV-G) with high activity, low chronicity, low complements, high anti-dsDNA → active severe lupus nephritis needing induction. Question explicitly: “Which induction regimen has demonstrated superior renal response rates in this clinical scenario?” implying evidence-based regimen with proven superiority over standard MMF+steroids.\nThe AURORA-1 trial showed that voclosporin added to MMF and steroids improved complete renal response vs MMF+steroids alone across proliferative classes, matching the rationale and keyed answer C. MMF+steroids (A) and Euro-Lupus cyclophosphamide+steroids (B) are acceptable standard inductions but have not been shown superior to MMF+steroids in this specific head‑to‑head way in this setting. Rituximab (D) and belimumab with cyclophosphamide (E) lack strong RCT data demonstrating superior induction response versus MMF+steroids for initial treatment of active Class IV-G LN.\nThus, a unique best option exists and matches the key.\nMain medical accuracy issue: none; summary of AURORA results is accurate at board level, though real‑world guideline adoption is evolving.\nMinimal fix: Add phrase “based on randomized controlled trial evidence showing superiority over MMF plus glucocorticoids alone” to the stem to emphasize the trial-comparison context.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-007", "question": "A 72-year-old man is admitted to the ICU with septic shock from pneumonia. Despite adequate fluid resuscitation and norepinephrine at 0.5 mcg/kg/min, MAP remains 58 mmHg. Echocardiography shows hyperdynamic left ventricle with EF 75%, small LV cavity, and IVC diameter of 0.8 cm with >50% respiratory variation. Lactate is 6.2 mmol/L. Which vasopressor strategy is most appropriate?", "options": ["Add vasopressin 0.03 units/min", "Add epinephrine infusion", "Add phenylephrine infusion", "Add angiotensin II infusion", "Increase norepinephrine to maximum dose before adding second agent"], "answer": "A", "answer_index": 0, "explanation": "Current sepsis guidelines recommend adding vasopressin (up to 0.03 units/min) as the second-line vasopressor when norepinephrine fails to achieve target MAP, typically when norepinephrine exceeds 0.25-0.5 mcg/kg/min. Vasopressin acts via V1 receptors independent of catecholamine pathways, which may be downregulated in sepsis. The VASST trial showed potential mortality benefit in less severe septic shock. The echocardiographic findings suggest adequate volume status (small IVC with variation indicates fluid responsiveness is exhausted). Angiotensin II is reserved for refractory vasodilatory shock after multiple agents. Phenylephrine may reduce cardiac output.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Septic shock with MAP 58 mmHg despite “adequate fluid resuscitation” and norepinephrine at 0.5 mcg/kg/min; echocardiogram shows hyperdynamic LV, high EF, small LV cavity, collapsible IVC (consistent with distributive shock with likely fluid-responsiveness remaining but question is explicitly about vasopressor strategy); lactate markedly elevated. Norepinephrine is already at a moderate–high dose within the range where guidelines suggest adding a second agent rather than escalating further.\\nAmong options, vasopressin 0.03 units/min is guideline-consistent as the preferred second-line vasopressor in septic shock when NE is inadequate. Epinephrine is reasonable but typically used after or in addition to vasopressin, or when cardiac dysfunction is present, which is not the case here. Phenylephrine is generally avoided in septic shock except specific scenarios (e.g., arrhythmias). Angiotensin II is reserved for refractory shock after multiple agents. “Increase norepinephrine to maximum” contradicts recommendations favoring earlier multimodal vasopressor therapy.\\nMain medical/logical issue: Minor echo interpretation error in the explanation (collapsible IVC suggests further fluid responsiveness, not that fluid responsiveness is exhausted) but this doesn’t affect the vasopressor choice.\\nMinimal fix: Correct the explanation to state that IVC findings suggest ongoing fluid responsiveness rather than exhausted fluid responsiveness.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Septic shock with MAP 58 mmHg despite “adequate fluid resuscitation” and norepinephrine at 0.5 mcg/kg/min; echocardiogram shows hyperdynamic LV, high EF, small LV cavity, collapsible IVC (consistent with distributive shock with likely fluid-responsiveness remaining but question is explicitly about vasopressor strategy); lactate markedly elevated. Norepinephrine is already at a moderate–high dose within the range where guidelines suggest adding a second agent rather than escalating further.\nAmong options, vasopressin 0.03 units/min is guideline-consistent as the preferred second-line vasopressor in septic shock when NE is inadequate. Epinephrine is reasonable but typically used after or in addition to vasopressin, or when cardiac dysfunction is present, which is not the case here. Phenylephrine is generally avoided in septic shock except specific scenarios (e.g., arrhythmias). Angiotensin II is reserved for refractory shock after multiple agents. “Increase norepinephrine to maximum” contradicts recommendations favoring earlier multimodal vasopressor therapy.\nMain medical/logical issue: Minor echo interpretation error in the explanation (collapsible IVC suggests further fluid responsiveness, not that fluid responsiveness is exhausted) but this doesn’t affect the vasopressor choice.\nMinimal fix: Correct the explanation to state that IVC findings suggest ongoing fluid responsiveness rather than exhausted fluid responsiveness.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-008", "question": "A 29-year-old primigravida at 34 weeks gestation presents with sudden-onset severe headache and right-sided weakness. Blood pressure is 178/112 mmHg. CT head shows left parietal intracerebral hemorrhage with surrounding edema. MRV demonstrates absence of flow in the superior sagittal sinus and left transverse sinus consistent with cerebral venous thrombosis. Platelet count is 82,000/μL, LDH is elevated, and peripheral smear shows schistocytes. Which is the most appropriate immediate management?", "options": ["Emergent cesarean delivery followed by therapeutic anticoagulation", "Therapeutic anticoagulation with unfractionated heparin", "Platelet transfusion followed by decompressive craniectomy", "Plasma exchange followed by anticoagulation", "Magnesium sulfate and antihypertensives with delayed anticoagulation"], "answer": "A", "answer_index": 0, "explanation": "This patient has cerebral venous thrombosis complicated by hemorrhagic transformation in the setting of HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) evidenced by thrombocytopenia, elevated LDH, and schistocytes. The definitive treatment for HELLP is delivery. While anticoagulation is standard for CVT even with hemorrhage, the underlying HELLP syndrome will not resolve without delivery and may worsen, increasing bleeding risk. Emergent cesarean delivery addresses the root cause, after which therapeutic anticoagulation can be safely initiated. Plasma exchange is for TTP, not HELLP. Delaying anticoagulation without addressing HELLP is inappropriate.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: K (miskeyed), secondary U. Verdict on keyed answer: Miskeyed; B is the best-supported immediate management from the written stem. Key stem clues: 34-week pregnant woman with acute severe headache, focal deficit, CT showing parietal intracerebral hemorrhage, MRV-confirmed cerebral venous thrombosis, platelets 82,000/μL, elevated LDH, schistocytes. The question asks for the most appropriate immediate management. In cerebral venous thrombosis, standard of care is therapeutic anticoagulation with heparin even in the presence of intracerebral hemorrhage, unless there is a clear, immediate obstetric indication for delivery. The stem suggests HELLP but does not provide blood pressures or liver enzyme data typical of severe preeclampsia/HELLP (AST/ALT not mentioned), nor any maternal/fetal distress mandating emergent cesarean. Thus, choosing emergent cesarean as the “immediate” step over initiating anticoagulation is not clearly justified by the given data. Medical accuracy: the explanation correctly contrasts HELLP vs TTP and notes anticoagulation for CVT, but overstates the need for emergent delivery from the limited labs provided. Minimal fix: add clear severe preeclampsia/HELLP criteria and explicit indication for emergent delivery, or change the key to B while clarifying that immediate anticoagulation is the first step.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (miskeyed), secondary U. Verdict on keyed answer: Miskeyed; B is the best-supported immediate management from the written stem. Key stem clues: 34-week pregnant woman with acute severe headache, focal deficit, CT showing parietal intracerebral hemorrhage, MRV-confirmed cerebral venous thrombosis, platelets 82,000/μL, elevated LDH, schistocytes. The question asks for the most appropriate immediate management. In cerebral venous thrombosis, standard of care is therapeutic anticoagulation with heparin even in the presence of intracerebral hemorrhage, unless there is a clear, immediate obstetric indication for delivery. The stem suggests HELLP but does not provide blood pressures or liver enzyme data typical of severe preeclampsia/HELLP (AST/ALT not mentioned), nor any maternal/fetal distress mandating emergent cesarean. Thus, choosing emergent cesarean as the “immediate” step over initiating anticoagulation is not clearly justified by the given data. Medical accuracy: the explanation correctly contrasts HELLP vs TTP and notes anticoagulation for CVT, but overstates the need for emergent delivery from the limited labs provided. Minimal fix: add clear severe preeclampsia/HELLP criteria and explicit indication for emergent delivery, or change the key to B while clarifying that immediate anticoagulation is the first step.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-009", "question": "A 14-year-old girl presents with 3 months of progressive fatigue, arthralgia, and facial rash. Laboratory evaluation reveals ANA 1:1280 (homogeneous pattern), anti-dsDNA positive, anti-Smith positive, C3 45 mg/dL (normal 90-180), C4 6 mg/dL (normal 10-40), and anti-C1q antibodies positive. Urinalysis shows 2+ protein and 10-15 RBCs/hpf. She is diagnosed with juvenile-onset systemic lupus erythematosus. The presence of anti-C1q antibodies in this patient most specifically predicts which disease manifestation?", "options": ["Neuropsychiatric lupus", "Proliferative lupus nephritis", "Antiphospholipid syndrome", "Lupus pneumonitis", "Autoimmune hemolytic anemia"], "answer": "B", "answer_index": 1, "explanation": "Anti-C1q antibodies have the highest specificity for lupus nephritis, particularly proliferative forms (Class III/IV). Studies demonstrate that anti-C1q antibodies have a negative predictive value approaching 100% for active renal disease-their absence essentially excludes active nephritis. The combination of anti-C1q with anti-dsDNA antibodies and low complement strongly predicts proliferative nephritis. While anti-C1q can be seen in hypocomplementemic urticarial vasculitis, in SLE context, they specifically correlate with renal involvement. Anti-ribosomal P antibodies are more associated with neuropsychiatric lupus.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 14-year-old with new juvenile SLE; strongly positive ANA, anti-dsDNA, anti-Smith; markedly low C3/C4; positive anti-C1q antibodies; question asks what anti-C1q most specifically predicts. In SLE, anti-C1q antibodies show the strongest and most specific association with lupus nephritis, particularly active proliferative (class III/IV) disease and correlate with hypocomplementemia and dsDNA titers. None of the alternatives (neuropsychiatric lupus, APS, lupus pneumonitis, autoimmune hemolytic anemia) have a well-established, specific association with anti-C1q. Neuropsychiatric lupus is more classically linked to anti-ribosomal P; APS to antiphospholipid antibodies; autoimmune hemolytic anemia to warm IgG autoantibodies; lupus pneumonitis lacks a unique serologic marker. Therefore B is uniquely and clearly best and matches the key.\\nMain logical issue(s): None; the item is well-posed and discriminatory.\\nMain medical accuracy issue(s): None significant; explanation correctly describes specificity and negative predictive value for active nephritis.\\nMinimal fix: Optionally specify “active proliferative lupus nephritis (class III/IV)” in choice B to further emphasize the intended association.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 14-year-old with new juvenile SLE; strongly positive ANA, anti-dsDNA, anti-Smith; markedly low C3/C4; positive anti-C1q antibodies; question asks what anti-C1q most specifically predicts. In SLE, anti-C1q antibodies show the strongest and most specific association with lupus nephritis, particularly active proliferative (class III/IV) disease and correlate with hypocomplementemia and dsDNA titers. None of the alternatives (neuropsychiatric lupus, APS, lupus pneumonitis, autoimmune hemolytic anemia) have a well-established, specific association with anti-C1q. Neuropsychiatric lupus is more classically linked to anti-ribosomal P; APS to antiphospholipid antibodies; autoimmune hemolytic anemia to warm IgG autoantibodies; lupus pneumonitis lacks a unique serologic marker. Therefore B is uniquely and clearly best and matches the key.\nMain logical issue(s): None; the item is well-posed and discriminatory.\nMain medical accuracy issue(s): None significant; explanation correctly describes specificity and negative predictive value for active nephritis.\nMinimal fix: Optionally specify “active proliferative lupus nephritis (class III/IV)” in choice B to further emphasize the intended association.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-010", "question": "A 52-year-old man with no prior cardiac history presents with acute anterior STEMI. Primary PCI reveals 100% occlusion of the proximal LAD with TIMI 0 flow. After successful stenting with TIMI 3 flow restoration, he develops cardiogenic shock with blood pressure 78/52 mmHg, heart rate 112 bpm, and cardiac index 1.6 L/min/m². Echocardiography shows akinesis of the anterior wall, apex, and septum with EF 20%. He is started on norepinephrine and dobutamine. Despite escalating support, he remains in refractory shock. Which mechanical circulatory support device provides the greatest degree of left ventricular unloading?", "options": ["Intra-aortic balloon pump", "Impella CP", "TandemHeart", "Veno-arterial ECMO", "Impella 5.5"], "answer": "E", "answer_index": 4, "explanation": "Impella 5.5 provides up to 5.5 L/min of forward flow and the greatest degree of LV unloading among the options by actively aspirating blood from the LV and ejecting it into the ascending aorta. This reduces LV end-diastolic pressure, wall stress, and myocardial oxygen demand while maintaining systemic perfusion. VA-ECMO provides excellent systemic support but increases LV afterload and may worsen pulmonary edema without LV venting. TandemHeart provides good support but requires transseptal puncture. Impella CP provides only 3-4 L/min. IABP provides modest afterload reduction with minimal flow augmentation (0.5 L/min).", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Large anterior STEMI with EF 20%, cardiogenic shock refractory to inotropes/vasopressors; question explicitly asks: “Which mechanical circulatory support device provides the greatest degree of left ventricular unloading?” The options list various MCS devices with differing LV unloading capacities. Among these, Impella 5.5 is known to provide the highest active LV forward flow (up to ~5.5 L/min), directly unloading the LV by aspirating blood from the LV and expelling into the ascending aorta. Impella CP has lower maximum flow (≈3–4 L/min); IABP offers only modest afterload reduction and minimal flow augmentation; TandemHeart unloads the left atrium rather than directly the LV; VA-ECMO increases LV afterload and can worsen LV distension unless vented.\\nMain logical issues: None; the stem clearly asks a comparative, device-specific property (degree of LV unloading), and the hemodynamic scenario is supportive but not essential to the discriminating feature.\\nMain medical accuracy issues: None significant; device descriptions and comparative flows/unloading are consistent with current knowledge.\\nMinimal fix: Clarify the comparison in the stem (e.g., “Among the following MCS options, which provides the greatest direct LV unloading?”) to stress the direct LV unloading mechanism, though the current version is already clear.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Large anterior STEMI with EF 20%, cardiogenic shock refractory to inotropes/vasopressors; question explicitly asks: “Which mechanical circulatory support device provides the greatest degree of left ventricular unloading?” The options list various MCS devices with differing LV unloading capacities. Among these, Impella 5.5 is known to provide the highest active LV forward flow (up to ~5.5 L/min), directly unloading the LV by aspirating blood from the LV and expelling into the ascending aorta. Impella CP has lower maximum flow (≈3–4 L/min); IABP offers only modest afterload reduction and minimal flow augmentation; TandemHeart unloads the left atrium rather than directly the LV; VA-ECMO increases LV afterload and can worsen LV distension unless vented.\nMain logical issues: None; the stem clearly asks a comparative, device-specific property (degree of LV unloading), and the hemodynamic scenario is supportive but not essential to the discriminating feature.\nMain medical accuracy issues: None significant; device descriptions and comparative flows/unloading are consistent with current knowledge.\nMinimal fix: Clarify the comparison in the stem (e.g., “Among the following MCS options, which provides the greatest direct LV unloading?”) to stress the direct LV unloading mechanism, though the current version is already clear.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]